anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators will recruit 110 adults with painful diabetic peripheral neuropathy. All will have their medical treatment optimized by a pain medicine specialist before being randomly assigned to either an 8-week group MBSR program or a wait-list. All participants will complete self-report questionnaires, provide a hair sample for cortisol measurements and a blood sample to measure glycemic index. We will be collecting outcome data for both groups. Patients randomized to MBSR will have data collected at 4 time points: 1) before medical optimization; 2) after medical optimization and before the MBSR group intervention begins, 3) 2 weeks after the group intervention; and 4) 3 months following completion of MBSR. Patients randomized to control will have data collected at 6-7 time points depending on when are participants enrolled in the trial: 1) before medical optimization; 2) after medical optimization and before the MBSR group intervention begins; 3) 2 weeks after the group intervention; 4) 3 months following completion of MBSR; 5) Re-test before control group intervention begins; 6) 2 weeks after control group intervention; and 7) 3 months after control group intervention.

The primary hypothesis is that after all patients are medically optimized, those randomized to MBSR will have a 30% higher incidence of clinically significant (≥1.0 decrease in mean BPI interference score) improvement (responders) compared to controls measured 3 months following completion of MBSR. A significant change is defined as ≥ 1 decrease in BPI interference score. A one point change on the Interference Scale, has been recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) group as a minimally clinically important change. This design controls for the effect of time and disease fluctuation, regression to the mean, and the effect of testing. In this preliminary research, where our primary goal is to establish proof of concept and obtain data needed to plan a comparative trial, we are not controlling for the placebo effect. We believe that a wait-list controlled study is the necessary foundation on which to build a rigorous program of research.
Patients undergoing esophagogastroduodenoscopy (EGD) for initial diagnosis of H.pylori infection or post therapy confirmation of eradication will be eligible to participate in the trial. Two sets of biopsies will be taken: one set for histological analysis and one set for rapid urease test (RUT) analysis. The two results will be used as a gold standard composite score in determining the presence of H.pylori bacteria in the stomach. The Urea Breath Test (UBT) using the Exalenz Dual Mode BreathID Hp System will also be performed within a week of the biopsy. The outcome of the UBT will be compared to composite score of the biopsy and the accuracy of the UBT will be evaluated. The UBT will be performed using breath collection bags, where the subject will be asked to breathe into the bags before and after ingestion of the 13C-labelled urea.
FIELD: medicine, cosmetics and sports. SUBSTANCE: plaster has supporting layer, plaster mass applied to supporting layer and protective layer. Supporting layer is manufactured from polymer material and provided with cover preventing volatile compounds of plaster mass from penetration into environment in the process of applying plaster to individual's skin. Plaster mass is composed of polymer layer within which fir oil is uniformly distributed. Fir oil is used as active substance. Plaster may be used for acting upon skin and subcutaneous tissues (endermic and adermic) as analgesic possessing heating effect. EFFECT: wider range of use and effectiveness and simplified structure. 1 ex
Lifelong immunosuppression, cytotoxic effects of some immunosuppressive drugs, and opportunistic oncogenic viruses increase malignancy risks in solid organ recipients. The risk of myeloid neoplasms including chronic myeloid leukemia (CML) is also increased in this patient population. Tyrosine kinase inhibitors (TKIs), the key element of CML therapy, should be used cautiously in transplantation patients as they may interact with calcineurin inhibitors. With this report, a 63-year-old female kidney transplant recipient who developed CML 9 years after kidney transplantation is presented. CML in this patient was treated with a slightly reduced dose of imatinib (300 mg) due to concerns of adverse events including its interaction with tacrolimus. Deep molecular response (DMR) was achieved at 12 months under imatinib treatment. The patient is still in DMR after 30 months of follow-up, and she did not experience any adverse events or acute rejection episodes. CML and the use of TKIs in kidney transplant patients have been discussed with an extensive literature review. In this patient population, TKIs are generally well tolerated with achievement of treatment responses and good prognosis. Graft functions are also well maintained as long as drug interactions are monitored.
Despite increasing concerns regarding the harmful effects of plastic-induced gut injury, mechanisms underlying the initiation of plastic-derived intestinal toxicity remain unelucidated. Here, mice were subjected to long-term exposure to polystyrene nanoplastics (PS-NPs) of varying sizes (80, 200, and 1000 nm) at doses relevant to human dietary exposure. PS-NPs exposure did not induce a significant inflammatory response, histopathological damage, or intestinal epithelial dysfunction in mice at a dosage of 0.5 mg/kg/day for 28 days. However, PS-NPs were detected in the mouse intestine, coupled with observed microstructural changes in enterocytes, including mild villous lodging, mitochondrial membrane rupture, and endoplasmic reticulum (ER) dysfunction, suggesting that intestinal-accumulating PS-NPs resulted in the onset of intestinal epithelial injury in mice. Mechanistically, intragastric PS-NPs induced gut microbiota dysbiosis and specific bacteria alterations, accompanied by abnormal metabolic fingerprinting in the plasma. Furthermore, integrated data from mass spectrometry imaging-based spatial metabolomics and metallomics revealed that PS-NPs exposure led to gut dysbiosis-associated host metabolic reprogramming and initiated intestinal injury. These findings provide novel insights into the critical gut microbial-host metabolic remodeling events vital to nanoplastic-derived-initiated intestinal injury.
Medications that inhibit CYP3A could increase plasma mifepristone concentrations and dose reduction of KORLYM may be required. 

Ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir and fosamprenavir, clarithromycin, conivaptan, lopinavir /ritonavir, posaconazole, saquinavir, telithromycin, or voriconazole may increase exposure to mifepristone. Caution should be used when strong CYP3A inhibitors are prescribed in combination with KORLYM. The benefit of concomitant use of these agents should be carefully weighed against the potential risks. The dose of KORLYM should be limited to 900 mg, and strong inhibitors of CYP3A should be used only when necessary. [See Dosage and Administration (2.4), Warnings & Precautions (5.6), and Clinical Pharmacology (12.3)]
PURPOSE: To obtain an antitumor compound having a tumor cell multiplication- inhibiting activity and a P-glucoprotein function-inhibiting action and useful as an active ingredient for antitumor agents, etc., by extracting Taxus cuspidata Sieb. et. Zucc. of Japan, etc. CONSTITUTION: This compound of formula I, preferably a compound of formula II. The compound is obtained e.g. by extracting the branches, etc., of Taxus cuspidata Sieb. et. Zucc. with ethanol, adding a salt aqueous solution to the extract, extracting the aqueous solution with toluene, concentrating and drying the extracted toluene layer, dissolving the residue in hexane/acetone, and subsequently subjecting the solution to a column chromatographic separation treatment, etc. When used as a medicine, the compound is preferably orally administered at a daily dose of approximately 1-100mg.
Musculoskeletal conditions are a leading cause of disability in the United States accounting for more than 130 million patient visits to healthcare providers annually. Rotator cuff tears are one of the most common causes of pain and disability of the upper extremity. Impaired motor control of the shoulder girdle muscles with concomitant instability often exists prior to any surgical procedure. Re-tears and/or attenuation after rotator cuff repairs occur relatively frequently and may compromise the functional result. Loading of the UE during rehabilitation, thus the repair site, following the surgical procedure has been implicated in these complications Conventional shoulder rehabilitation protocols with the human-human interface do not possess the ability to systematically quantify dosing and progression for patients in the subacute stages thus, potentially overloading the repair site. No evidence-based research exists comparing outcomes of specific rehabilitative training protocols in these post-surgical patients. Consensus statements conclude, �a need for clinical trials, and validated outcome measures is essential�.

Advances in robotics technology offer unprecedented opportunities to improve rehabilitation pathways, but until now these technologies have focused primarily on neurological disease. The MIT Newman Laboratory for Biomechanics and Human Rehabilitation upper extremity (UE) robot is an impedance controlled, back-drivable, oblique-vertical vertical robot that has been designed such that it can safely exert controlled, graded forces to move or guide a limb, functioning in passive, active-assistive, active and resistive modes, providing objective data on the motion. A major advantage is its capacity for real-time, graded changes based on patient input, providing stability against random perturbations, increasing or withdrawing assistance and allowing for dose-specific treatment. The vertical robot device has been shown to be safe and well tolerated without any adverse effects such as shoulder pain.

Goal-directed, quantifiable rehabilitation protocols for redevelopment of function through improved range of motion, strength and motor control are lacking in patients with musculoskeletal impairments. The successful robotic-assisted rehabilitation of the acute and chronic, severe impairment provides an impetus for applying this technology to UE musculoskeletal impairments. The ability to objectively control and measure the dosing and progression during the rehabilitation process is a valuable tool in the advancement of evidence�based rehabilitation interventions The proposed pilot clinical trial will determine if 8-weeks of robotic rehabilitation improves the rate and quality of recovery of range of motion, strength, and function following rotator cuff repair compared with a conventional physical therapy rehabilitation protocol.
Allogeneic MSCs being used in current human clinical trials are nonclonal, i.e., such MSCs may have other types of cells in the final stem cell product. Some concerns exist about the heterogeneity of these nonclonal MSCs that are isolated and expanded by the conventional density-gradient centrifugation method. Recently, we developed a new protocol, called the subfractionation culturing method (SCM), to generate single-cell-derived clonal MSC (cMSC) lines from whole bone marrow aspirate without employing any centrifugation step for mononuclear cells and enzyme treatment process. This method allowed us to rapidly establish single-cell-derived human clonal MSC (hcMSC) lines from raw bone marrow aspirates and to establish a library of these hcMSC lines (Song et al., 2008).

The goal of this study is to evaluate the safety of allogeneic cMSCs established by the SCM and manufactured in GMP facility. This phase I clinical trial is a multicenter, single dose study of cMSC (1 x 10e6 cMSCs/Kg recipient's bodyweight). Clonal MSCs will be infused to acute or chronic GVHD patients via an intravenous injection. Every patients will receive the same treatment
To provide a novel jet lag improving agent.SOLUTION: The technical features of the present invention for solving the above problem are as follows. 1. A jet lag improving agent contains a passiflora extract (excluding those containing harmin). 2. A composition for food or drink contains the jet lag improving agent as described in 1. above. 3. A pharmaceutical composition contains the jet lag improving agent as described in 1. above. 4. An external skin composition contains the jet lag improving agent described in 1. above.SELECTED DRAWING: None
The present invention relates to the provision of a medicament and of a diagnostic agent obtained by proteome analysis, preferably containing at least two different chemokine receptor ligands or chemokine receptor antibodies, and further to the use of at least two different chemokine receptor ligands, chemokine receptor antibodies and/or two different chemokine receptors. As inhibitors, the medicament preferably contains ligands or antibodies of at least two chemokine receptors or the related algorithms of the surface chemokine receptor proteome, and the use of at least one chemokine receptor ligand and/or chemokine receptor, peptides and antibodies and their use for the diagnostics and therapy of tumor diseases and inflammatory diseases. By way of analogy, clusters of analyzed tumor cell surface proteomes, such as ectoproteases, adhesion molecules or various receptor types, can also be used.  
     The invention relates to a method for the purpose of diagnosis and therapy and the medical and industrial use of chemokines and their corresponding receptors, their antagonists including antibodies was found to inhibit cancer growth including metastatic spread, and to suppress inflammatory and auto-immune diseases. The method is based on the finding that chemokines act on specific tumor and inflammation cells via autocrine, paracrine and endocrine routes through the disease-specific constellation of the chemokine receptor proteome. Primary and secondary tumors as well as specific inflammation cells are controlled with respect to their migration and proliferation behavior. By diagnostically detecting the chemokines whose expression and regulation is locally increased and the presence of the chemokine receptor compositions, the possibility arises of critically suppressing or completely preventing cancer growth, metastatic spread of tumors as well as inflammatory and auto-immune diseases.
INTRODUCTION: Retropharyngeal abscess (RPA) is an uncommon infection in older people, which usually presents with localized upper airway symptoms.
CASE PRESENTATION: We present a case of RPA in a 69-year-old frail woman with co-morbidities, who presented atypically with delirium. She initially complained of general symptoms of malaise, body aches and general decline. Her symptoms progressed to hypoactive delirium before she started to localize her complaints to the upper airway. The delirium presentation of RPA is not commonly reported in the literature. Co-morbidities and frailty are likely to be the underlying risk factors for delirium presentation in this case. Most of the RPA cases reported in older people in the literature presented typically with localized symptoms, however these cases had lower burden of morbidities and reported no frailty. In our case report, poor mouth hygiene and dental caries were thought to be the source of infection. Early intervention with antibiotic treatment for total of four weeks resulted in a full recovery.
CONCLUSION: RPA may present with delirium in older people with frailty and co-morbidities. Poor oral hygiene and dental caries, if left untreated, may progress into serious deep space neck infection.
The present invention relates to the treatment of cancer and particularly the neuroblastoma. In thus study, the inventors hypothesized that CD47 expression would interfere with the contribution of macrophage to the therapeutic effect of anti-OAcGD2 mAbs. They found that NB cells up-regulate CD47 expression upon 8B6 mAb immunotherapy in vivo, allowing them to escape mAb 8B6-mediated ADP. Next, they demonstrate that an anti-SIRPα antibody that blocks the binding of CD47 to SIRPα enables macrophages to phagocyte anti-OAcGD2-opsonised CD47-expressing NB cells in vitro. As a result, the combination of CD47 blocking with the targeting of OAcGD2-positive NB cells greatly reduces tumor growth in syngeneic mice. These results suggest that the combination of anti-OAcGD2 mAbs with phagocytosis checkpoints inhibitors may represent a very effective regimen to achieve for lasting responses in a greater number of patients. Thus, the present invention relates to a combination of an anti-O-acetylated disialoganglioside (OAcGD2) compound and an anti-SIRP-alpha/CD47 compound for use in the treatment of a cancer in a subject in need thereof.
The present invention relates to crystal capsules for treating cardiovascular and cerebrovascular diseases, which belong to new Tibetan medicines for treating cardiovascular and cerebrovascular diseases. In the present invention, nine medicinal materials are taken and extracted by three modes; in the formula, milkvetch root, earthworm, sappanwood and achyranthes root are extracted by water for three times to obtain three extracted solutions, and then, the three extracted solutions are mixed, filtered, concentrated, baked and pulverized; chuanxiong rhizome, Chinese angelica and rhodiola root are extracted for three times by ethanol whose concentration is 70% through backflow to obtain three extracted solutions, the three extracted solutions are mixed, the pressure is reduced, and then, the ethanol is recovered and concentrated into paste to be baked and pulverized; bile arisaema is mixed with saffron after being baked to be pulverized; the three kinds of medicinal powder are evenly mixed proportionally, and then, auxiliary materials are added to the mixture to be encapsulated. The capsules of the present invention have the functions of promoting blood circulation, removing blood stasis, relieving palpitation, stabilizing mind, regularizing qi and blood and regularizing the balance function of blood, bile and the liver, and are suitable for treatment and prevention of coronary arteriosclerosis, coronary disease, ischemic heart disease and angina pectoris caused by diffusion of comprehensive hepatotoxicity to the heart, and hypertension, cerebral thrombosis and apoplexy sequelae caused by diffusion of comprehensive hepatotoxicity to the head. The capsules of the present invention have the advantages of convenient treatment, obvious effect and high healing rate, and diseases are not easy to recur. The capsules of the present invention can thoroughly relieve the disturbance of hypertension, heart disease, etc. caused by cardiovascular and cerebrovascular diseases.
Disclosed and claimed are toxins produced by novel Bacillus thuringiensis isolates designated B.t. PS92J, B.t. PS196S1, B.t. PS201L1, and B.t. PS201T6, which have dipteran and/or corn rootworm activity. Thus, the isolates, or mutants thereof, can be used to control such pests. Further, claimed are novel genes encoding these  delta -endotoxins, which can be expressed in other hosts. Expression of the  delta -endotoxins in such hosts results in the control of susceptible insect pests in the environment of such hosts.
Nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by nelfilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
Patients suspected of or diagnosed with systemic amyloidosis will be scanned by 11C-PIB or 18F-florbetapir PET/MR twice. One is before biopsy and treatment, and the other is after at least half a year of treatment.
PURPOSE: An adhesive agent is provided to ensure low water vapor permeability, enough ODT effect, and drug release property. CONSTITUTION: An adhesive agent(100) comprises a support(10) and an adhesive layer(20) with an adhesive polymer and a drug. The support sequentially comprises a polyester agent base layer(11), an inorganic oxide layer(12), and a polyester agent non-woven fabric layer(13). The thickness of the polyester agent base layer is 10um - 16um. The adhesive layer is laminated on the polyester agent non-woven fabric. The thickness of the inorganic oxide layer is 1-300 nm. The adhesive layer contains an organic liquid ingredient.
PURPOSE:The titled cosmetic, having improved feeling of use, capable of separating into three layers on standing and forming a homogeneous emulsion in use with shaking, and prepared by incorporating specific amounts of a polyoxyalkylene alkyl phenyl ether, a liquid oil, a pigment, a water-soluble salt and water as main constituents. CONSTITUTION:A cosmetic, e.g. a liquid foundation, prepared by incorporating 0.05-3.0wt% compound of formula I (R is 6-18C alkyl; R' is CH2CH2 or formula II; n is an integer 2-20), 3-25wt% liquid oil, e.g. a liquid higher aliphatic hydrocarbon, 0.5-15wt% pigment, e.g. titanium dioxide, 0.05-3.0wt% water-soluble salt, e.g. potassium dihydrogenphosphate, and 30-95wt% water as main constituents, and if necessary at most 25wt% ethyl alcohol, an oil-soluble or water- soluble dye and/or an ultraviolet light absorber. The cosmetic separates into three layers on standing to give a beautiful appearance, forms a homogeneous emulsion in use with shaking and shows a good feeling of use and cosmetic effect.
FIELD: medicine, experimental pharmacology, phytotherapy. SUBSTANCE: for prophylaxis and treatment of indicated diseases method involves administration of species infusion in the concentration 1:10. Infusion comprises the following components: big burdock roots, swampy cudweed herb, marsh-mallow roots, glabrous licorice roots, common oak bark, medicinal sweet clove herb, common motherwort herb, knot-grass herb, purple coneflower herb, colt's foot leaves, walnut leaves taken in the ratio = 2:1:2:2:2:2:1:1:1:2: 1, respectively. Infusion is given in the dose 0.3 ml per 100 g of body mass of laboratory animal for 10 days. Invention is directed for the enhanced effectiveness in prophylaxis and treatment of chronic pancreatitis and hepatitis developing simultaneously. EFFECT: enhanced effectiveness of method. 16 dwg, 3 ex
This study reports the results of a study evaluating a book-supported prevention program "Dominique's Handy Tricks" for anxiety disorders in children aged 9 to 12 years of age. This cognitive-behavioural program is delivered using a combination of story-based books and workshop sessions. The originality of the program comes from the use of story books that were not developed for anxiety management specifically. Every session is based on a story describing characters facing common stressors in childhood and how they managed to cope with their daily problems. In our randomized control trial with 46 children, participation in the program lead to a significant improvement in coping skills, self-efficacy, anxiety sensitivity, signs of anxiety and phobic avoidance. The theoretical and practical elements underlying the delivery of this primary prevention programs are described. It is suggested that such an approach, without any labelling specific to anxiety disorders, can be useful in universal primary prevention programs.